Intentional weight loss in overweight or obese patients with heart failure may improve outcomes.
Overweight and obesity are significant risk factors for developing heart failure.
The 'obesity paradox' suggests a higher BMI could be linked to better survival in established heart failure cases.
Recent trials of indicate that weight loss may lead to improved outcomes in these patients.
is associated with heart failure pathophysiology, affecting cardiac function and structure.
Accurate measures of fat accumulation are needed to identify patients who may benefit from anti-obesity treatments.
Simplified
Overweight and obesity are major risk factors for heart failure (HF), contributing to its development through metabolic, neurohormonal, haemodynamic, and inflammatory alterations. While overweight/obesity increases the risk of developing HF, its impact on patient outcomes remains complex. The "obesity paradox" suggests that a higher BMI may be associated with improved survival in patients with established HF. However, recent GLP-1 receptor agonist (GLP-1 RA) trials suggest that intentional weight loss positively influences outcomes in overweight/obese patients with HF. This seemingly contradictory evidence highlights the need for a deeper understanding of the mechanisms linking adiposity to HF outcomes. A more precise characterization of adiposity phenotypes using alternative and accurate measures of pathological fat accumulation is crucial in identifying individuals who may benefit most from anti-obesity treatments. In this context, recent research underscores the role of (EAT) in HF pathophysiology, as it directly influences cardiac function and structure through inflammatory, metabolic, and mechanical effects. This narrative review summarises current evidence on the impact of weight loss on HF outcomes, focusing on recent GLP-1 RA trial results. Additionally, it highlights epidemiological and molecular data supporting EAT as a novel adiposity measure that might allow refining patient selection for pharmacological weight-loss treatments. Finally, it emphasizes the need for future research to identify causal pathways linking alternative measures of visceral fat accumulation to HF outcomes. These efforts will be essential in optimizing the benefits of novel weight-loss treatments, ensuring effective and individualized therapeutic strategies for overweight or obese patients with HF.
Key numbers
0.59
Reduction in HF Worsening Events
Hazard Ratio for worsening HF events in patients with treated with semaglutide.
17,604
Patients in SELECT Trial
Total number of patients in the SELECT trial assessing semaglutide's impact.
39%
Weight Loss Impact on Quality of Life
Percentage reduction in heart failure hospitalization risk in type 2 diabetes patients.
Full Text
We can’t show the full text here under this license.
Declarations. Competing interests: DT reports receiving fees for serving on advisory boards from Amarin, Boehringer Ingelheim and Novo Nordisk, lecture fees from Eli Lilly, and travel support from AstraZeneca. FP reports receiving fees for serving on advisory boards from Novo Nordisk. He also serves as Guest Editor for the thematic collection to which the current manuscript has been submitted; as such, has not been involved in the peer review process for this article.
